^
Association details:
| Biomarker: | REST signature |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An expression based REST signature predicts patient survival and therapeutic response for glioblastoma multiforme
Excerpt:
...we developed an expression based REST signature and assessed its association with transcriptomics, genomics, drug sensitivity and clinical outcome for GBM in this article....Ponatinib, a tyrosine-kinase inhibitor for ABL approved to treat chronic myeloid leukemia also showed increased sensitivity in REST enhanced samples (Fig. 4A).
DOI:
10.1038/srep34556
